Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 32,954 shares at $13.00 ($429K) on 2026-03-09, disclosed to the SEC on 2026-03-11.
Seasonal sale ($429k) by Chief Financial Officer — this insider has traded TRDA in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.00 | 5,089 | $66K | 15.4% |
| 2 | $13.00 | 5,089 | $66K | 15.4% |
| 3 | $13.02 | 11,388 | $148K | 34.6% |
| 4 | $13.02 | 11,388 | $148K | 34.6% |
| Total | $13.01 avg | 32,954 | $429K | 100% |
| Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |
| TRDA | SELL | 2024-12-03 | $120K | — | Filing → |